Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 0 5 versus TRIACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 0 5 versus TRIACORT.
DEXONE 0.5 vs TRIACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist, binding to the glucocorticoid receptor (GR) and modulating gene expression through transactivation and transrepression. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, suppresses cytokine production (IL-1, IL-2, IL-6, TNF-alpha), and decreases immune cell migration and activation.
Adrenocorticosteroid; binds to glucocorticoid receptor, modulating gene expression to produce anti-inflammatory, immunosuppressive, and metabolic effects.
0.5 mg orally once daily, with gradual taper to lowest effective dose
10-20 mg orally once daily
None Documented
None Documented
3.0-4.5 hours; prolonged in hepatic impairment (up to 6-8 hours) or concurrent CYP3A4 inhibitors
2-3 h. The terminal elimination half-life is short, requiring thrice-daily dosing for sustained effect. Context: In patients with hepatic impairment, half-life may be prolonged up to 4-5 h.
Renal: 70-80% (mostly as 6β-hydroxydexamethasone); biliary/fecal: 10-15%
Primarily hepatic metabolism (>90%) with renal excretion of inactive metabolites (approximately 80% in urine, 20% in feces). Less than 5% of the parent drug is excreted unchanged in urine.
Category C
Category C
Corticosteroid
Corticosteroid